| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1097/00003246-200107001-00024 |
| P698 | PubMed publication ID | 11445737 |
| P2093 | author name string | Yan SB | |
| Dhainaut JF | |||
| P433 | issue | 7 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sepsis | Q183134 |
| drotrecogin alfa | Q412888 | ||
| P304 | page(s) | S69-74 | |
| P577 | publication date | 2001-07-01 | |
| P1433 | published in | Critical Care Medicine | Q5186605 |
| P1476 | title | Activated protein C versus protein C in severe sepsis | |
| P478 | volume | 29 |
| Q49125327 | Activated protein C in the treatment of sepsis |
| Q35642546 | An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures |
| Q36285943 | Animal models of sepsis: setting the stage |
| Q35990040 | Candidate-based proteomics in the search for biomarkers of cardiovascular disease |
| Q36349735 | Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma |
| Q43865671 | Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study |
| Q81470488 | Comment on "Early treatment with activated protein C for meningococcal septic shock: case report and literature review" by Hasin et al |
| Q77762835 | Drotrecogin alfa (activated) |
| Q36607385 | Drotrecogin alfa (activated) in the treatment of severe sepsis |
| Q34779800 | Drotrecogin alfa: a new approach in the treatment of severe sepsis |
| Q35850483 | Drotrecogin alfa: a role in emergency department treatment of severe sepsis? |
| Q36981698 | Drotrecogin alpha (activated): the treatment for severe sepsis? |
| Q24299161 | Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2 |
| Q34938586 | Emerging therapies in severe sepsis |
| Q35567223 | Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism |
| Q44417143 | Expression and function of the endothelial protein C receptor in human neutrophils |
| Q24201123 | Human recombinant activated protein C for severe sepsis |
| Q24235181 | Human recombinant activated protein C for severe sepsis |
| Q24202128 | Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients |
| Q36259598 | Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition |
| Q33754477 | New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study |
| Q36259602 | New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). |
| Q35030573 | Pharmacokinetics and clinical use of drotrecogin alfa (activated) in patients with severe sepsis |
| Q35030570 | Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated). |
| Q90270575 | Pravastatin Alleviates Radiation Proctitis by Regulating Thrombomodulin in Irradiated Endothelial Cells |
| Q35136144 | Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C. |
| Q40646976 | Protein C and thrombomodulin in human acute lung injury |
| Q81725856 | Protein C as an early marker of severe septic complications in diffuse secondary peritonitis |
| Q46610474 | Protein C concentrate to restore physiological values in adult septic patients. |
| Q34469113 | Role of human recombinant activated protein C and low dose corticosteroid therapy in sepsis |
| Q78772829 | Severe sepsis |
| Q52951509 | [Coagulation inhibitors in severe sepsis: state of the art]. |
| Q76379810 | [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain] |
Search more.